Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Shattuck Labs, Inc. STTK D&A

D&A at other companies

Aclaris TherapeuticsACRS

$102K-20.3%

Avalo TherapeuticsAVTX

$17K-87.4%

ZymeworksZYME

$176K-89.1%

AmgenAMGN

——

Other financials

Income statement

See full

Revenue-—

Operating income-$15.5M-8.0%

Net income-$14.8M-7.8%

EPS (diluted)-$0.13+51.9%

Balance sheet

See full

Cash & equivalents$90.4M+48.5%

Total debt$2.9M-9.5%

Total equity$95.8M+41.8%

Total assets$102.1M+32.3%

Cash flow

See full

Operating cash flow-$13.4M-11.6%

CapEx$63.0K—

Free cash flow-$13.5M-12.1%

Valuation

See full

Market cap$564.45M+1,131%

Enterprise value$476.92M-4,119%

P/S564.5×+554×

Profitability

See full

Operating margin-5,266.4%-9,520pp

Net margin-4,987.4%-8,966pp

FCF margin-4,140.8%-7,144pp

Returns & leverage

See full

Return on equity-61%-8.0pp

Debt / equity0×0.0×

Current ratio22.1×+13.0×

Questions, answered.

What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.